Axsome Therapeutics (AXSM)
239.62
+2.67 (1.13%)
Upcoming Events
Latest Headlines
BMO Capital Starts Axsome Therapeutics (AXSM) at Outperform
July 20, 2026 4:13 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
July 16, 2026 6:47 AM - StreetInsider
Form 8-K Axsome Therapeutics, For: Jul 15
July 15, 2026 7:05 AM - SEC Filing
FDA accepts Axsome drug application for cataplexy treatment
July 15, 2026 7:00 AM - StreetInsider
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
July 15, 2026 7:00 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
July 14, 2026 7:55 AM - StreetInsider
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
July 14, 2026 7:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
July 8, 2026 6:40 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $304 at RBC Capital
July 7, 2026 7:59 AM - StreetInsider
Axsome starts Phase 3 trial of solriamfetol in children with ADHD
July 7, 2026 7:00 AM - StreetInsider
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
July 7, 2026 7:00 AM - StreetInsider
Form 4 Axsome Therapeutics, For: Jul 01 Filed by: TABUTEAU HERRIOT
July 1, 2026 7:30 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: TABUTEAU HERRIOT
July 1, 2026 5:35 PM - SEC Filing
Axsome starts Phase 3 trial of solriamfetol for adolescent ADHD
June 26, 2026 7:00 AM - StreetInsider
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
June 26, 2026 7:00 AM - StreetInsider
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
June 18, 2026 7:00 AM - Globe NewsWire
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
June 18, 2026 7:00 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $300 at TD Cowen; 'Under-followed Pipeline Is Upside'
June 17, 2026 8:25 AM - StreetInsider
Axsome Therapeutics presents sleep disorder data at SLEEP 2026 conference
June 15, 2026 7:02 AM - StreetInsider
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
June 15, 2026 7:00 AM - StreetInsider
Form 4 Axsome Therapeutics, For: Jun 10 Filed by: JEFFS ROGER
June 11, 2026 8:34 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: JEFFS ROGER
June 11, 2026 5:10 PM - SEC Filing
Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
June 11, 2026 5:34 AM - StreetInsider
Form 4 Axsome Therapeutics, For: Jun 08 Filed by: Saad Mark E
June 10, 2026 9:50 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 08 Filed by: JEFFS ROGER
June 10, 2026 9:50 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 08 Filed by: Mahony Susan
June 10, 2026 9:49 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 08 Filed by: Coleman Mark
June 10, 2026 9:49 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: Mahony Susan
June 10, 2026 4:17 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: JEFFS ROGER
June 10, 2026 4:16 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: Coleman Mark
June 10, 2026 4:16 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: TABUTEAU HERRIOT
June 9, 2026 6:01 PM - SEC Filing
Form 8-K Axsome Therapeutics, For: Jun 05
June 9, 2026 5:21 PM - SEC Filing
Form 8-K Axsome Therapeutics, For: Jun 05
June 9, 2026 5:20 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 05 Filed by: Coleman Mark
June 9, 2026 5:19 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 05 Filed by: Mahony Susan
June 9, 2026 5:18 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 09 Filed by: TABUTEAU HERRIOT
June 9, 2026 5:17 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 09 Filed by: Pizzie Nick
June 9, 2026 5:17 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 05 Filed by: Saad Mark E
June 9, 2026 5:16 PM - SEC Filing
Form 4 Axsome Therapeutics, For: Jun 05 Filed by: JEFFS ROGER
June 9, 2026 5:16 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: Pizzie Nick
June 9, 2026 4:09 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: Mahony Susan
June 9, 2026 4:07 PM - SEC Filing
Morgan Stanley tracks prescription trends for US neurology drugs
June 5, 2026 8:59 AM - StreetInsider
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
June 4, 2026 7:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
June 4, 2026 6:40 AM - StreetInsider
Form 8-K Axsome Therapeutics, For: Jun 03
June 3, 2026 9:04 AM - SEC Filing
Axsome settles SUNOSI patent litigation, allows generics starting 2040
June 3, 2026 7:04 AM - StreetInsider
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
June 3, 2026 7:00 AM - StreetInsider
Form 4 Axsome Therapeutics, For: May 29 Filed by: Coleman Mark
June 2, 2026 7:00 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: Coleman Mark
June 2, 2026 4:10 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: Coleman Mark
June 1, 2026 4:06 PM - SEC Filing
Axsome partners with Headache Alliance for migraine awareness month
June 1, 2026 7:03 AM - StreetInsider
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
June 1, 2026 7:00 AM - StreetInsider
Form 144 Axsome Therapeutics, Filed by: Coleman Mark
May 29, 2026 4:09 PM - SEC Filing
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 27, 2026 7:00 AM - Globe NewsWire
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
May 26, 2026 7:00 AM - StreetInsider
Axsome Therapeutics Recognizes Mental Health Month
May 7, 2026 7:01 AM - Globe NewsWire
Form 4 Axsome Therapeutics, For: May 04 Filed by: Jacobson Mark L.
May 5, 2026 8:35 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L.
May 5, 2026 5:55 PM - SEC Filing
Form 144/A Axsome Therapeutics, Filed by: Jacobson Mark L.
May 5, 2026 5:54 PM - SEC Filing
Axsome Therapeutics (AXSM) PT Raised to $255 at Wells Fargo
May 5, 2026 8:55 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $242 at Morgan Stanley
May 5, 2026 8:00 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $267 at Needham
May 5, 2026 7:28 AM - StreetInsider
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 5, 2026 7:00 AM - Globe NewsWire
Axsome Therapeutics (AXSM) PT Raised to Street High $310 at Mizuho, Top Pick
May 5, 2026 6:05 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $300 at B.Riley
May 5, 2026 4:20 AM - StreetInsider
Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L.
May 4, 2026 5:43 PM - SEC Filing
Form 10-Q Axsome Therapeutics, For: Mar 31
May 4, 2026 5:05 PM - SEC Filing
Axsome Therapeutics (AXSM) PT Raised to $246 at Baird
May 4, 2026 4:17 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $302 at RBC Capital
May 4, 2026 4:07 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $280 at Oppenheimer
May 4, 2026 3:19 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $260 at Guggenheim
May 4, 2026 1:15 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $258 at Piper Sandler
May 4, 2026 12:23 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $275 at TD Cowen
May 4, 2026 12:06 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $270 at H.C. Wainwright
May 4, 2026 7:28 AM - StreetInsider
Form 8-K Axsome Therapeutics, For: May 04
May 4, 2026 7:08 AM - SEC Filing
Axsome Therapeutics (AXSM) Misses Q1 EPS by 43c
May 4, 2026 7:01 AM - StreetInsider
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 4, 2026 7:00 AM - Globe NewsWire
Axsome Therapeutics (AXSM) PT Raised to $255 at TD Cowen
May 1, 2026 11:25 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $241 at Baird
May 1, 2026 8:20 AM - StreetInsider
Axsome AUVELITY wins FDA approval for Alzheimer's agitation treatment
May 1, 2026 7:15 AM - StreetInsider
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
May 1, 2026 7:15 AM - Globe NewsWire
Form 8-K Axsome Therapeutics, For: Apr 30
April 30, 2026 5:19 PM - SEC Filing
Axsome Therapeutics (AXSM) PT Raised to $250 at Oppenheimer
April 30, 2026 5:15 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $217 at Morgan Stanley
April 30, 2026 3:23 PM - StreetInsider
Axsome receives FDA approval for AUVELITY to treat Alzheimer's agitation
April 30, 2026 2:06 PM - StreetInsider
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
April 30, 2026 2:06 PM - Globe NewsWire
Axsome Therapeutics (AXSM) Halted, News Pending
April 30, 2026 2:05 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Lowered to $228 at Mizuho
April 28, 2026 9:13 AM - StreetInsider
Form ARS Axsome Therapeutics, For: Dec 31
April 24, 2026 5:03 PM - SEC Filing
Form DEFA14A Axsome Therapeutics,
April 24, 2026 5:03 PM - SEC Filing
Form DEF 14A Axsome Therapeutics, For: Apr 24
April 24, 2026 5:02 PM - SEC Filing
Full Article List
